The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 1,398,616 share decrease in total short interest for DENTSPLY SIRONA Inc (XRAY - Get Report), to 8,220,629, a decrease of 14.54% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for XRAY at the 01/31/2017 settlement increased to 2,283,749, as compared to 1,436,936 at the 01/13/2017 report. That brought "days to cover" down to 3.60, a 46.23% decrease from the 6.69 days to cover calculated at the previous short interest data release.The below chart shows the historical "days to cover" for XRAY at previous short interest release dates: A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where XRAY had been shorted as a hedge. The chart below shows the one year performance of XRAY shares, versus its 200 day moving average. Looking at this chart, XRAY's low point in its 52 week range is $53.43 per share, with $65.83 as the 52 week high point — that compares with a last trade of $58.35. According to the ETF Finder at ETF Channel, XRAY makes up 1.69% of the XHE: SPDR S&P Health Care Equipment ETF, US Equities ETF (XHE) which is up by about 0.1% on the day Friday.
More from Stocks
What to Watch When Snap Reports Its Latest Results
Snap's user trends have stabilized, and its revenue has grown this year. Can it keep up the pace?
Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study
Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.
A Slow Tape Means Investors Need to Find Other Things to Do
When the tape slows down it's a dangerous time to be trading.